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The aim  o f  the w ork is to present regenerative m edicine achievem ent as an alternative SUI treatm ent and  the 
variety o f in jected cells type as well as injection techniques itse lf with the analysis o f  their quality and  possib le  the 
mechanism  in which they reduce urinary incontinence symptoms.
For over a decade numerous authors declare use o f  different type o f autologous m esenchym al-derived stem  cells 
(AMDC) in male and  female SUI. The leakage im provem ent reached 80%, despite the num ber o f  in jected cells as 
well as the injection technique. Im portant sub ject in the A M D C  treatm ent is the precise cell material injection into 
the selected spo t which m ight be possib le with the use o f the endoscopic assisting robot.
The robotic supported system  for cells procedure m ight bring the m issing percentage in reaching the goal in SUI 
treatment.
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Streszczenie
Celem p racy je s t przedstaw ienie osiągnięć m edycyny regeneracyjnej jako  alternatywnej terapii w  wysiłkowym  
nietrzymaniu m oczu (WNM). Dokonany p rzeg ląd literatury prob lem u wskazuje na różnorodność podaw anych linii 
kom órkowych, ich rodzaju, ja k  i sam ej techniki iniekcji z  analizą jakośc i i ewentualnego mechanizmu, w  którym  
zm niejszeniu uległy ob jaw y nietrzymania moczu.
O d  p onad  dziesięciu la t w ielu au torów  deklaruje korzystanie z  różnych rodza jów  autologicznych m ezenchym alnych  
kom órek macierzystych (AMDC autologoue m uscle derived stem  cells) w  leczeniu m ężczyzn i kob ie t z  WNM. 
Poprawa utrzymania m oczu sięga wg niektórych źróde ł 80%, niezależnie o d  liczby wstrzykniętych komórek, oraz 
sposobu ich podania. Ważnym zagadnieniem  w  leczeniu z  użyciem AM DC, je s t precyzyjne podanie m ateriału  
kom órkow ego do wybranego miejsca (zwieracza cew ki moczowej), które można udoskonalić stosując endoskopow o  
w spom agany system  robota.
Zastosow anie w w  system u m og łoby popraw ić technikę podania materiału kom órkow ego i zob iektyw izować wyniki 
leczenia.
Słowa kluczowe: komórki macierzyste / wysiłkowe nietrzymanie moczu /
/ endoskopia / robotyka
Urinary incontinence is symptom which has strong impact 
on the quality of  life, both in women and in men. In the case 
of  female stress urinary incontinence (SUI), apart from pelvic 
floor physiotherapy, pessaries and others surgery is the one 
method of  treatment [1]. Until recently, the Burch procedure 
(colposuspension) was the “gold standard”. Long-term 
observations of  up to 30 years allowed to believe that no new 
treatment will achieve such a high (up to 80%) effectiveness of  
therapy. Laparoscopic modification allowed to minimize the side 
effects (including post-surgery pain and bleeding) as well as the 
duration of  surgery and hospitalization. A limiting factor for this 
technique is still the learning curve, particularly laparoscopic 
access, which can significantly impact the final effect of  urinary 
continence. Further research were oriented at simplification 
of  the technique, while maintaining high effectiveness of  the 
procedure. In the nineties, synthetic tapes were introduced; the 
application techniques included tension free vaginal tape (TVT) 
and transobturator tape (TOT) [2, 3]. The tape material resistance 
ensured long-term therapeutic effect. Yet, there was a problem 
resulting from tissue barrier of  the immune reaction to the foreign 
body. Complications, i.e. erosion of  the tape with accompanying 
fistulas, symptoms of  dysuria, and even generalized infection 
(sepsis) induced the researchers to seek new, biodegradable or 
autologous materials as prosthesis for the urethra and/or vaginal 
wall [4, 5].
Stem cells therapy for management o f male stress urinary 
incontinence
Despite improvements in surgical techniques and 
implementation of  minimally invasive procedures, male stress 
urinary incontinence (MSUI) affects a substantial number 
of  patients after prostatic surgery. Historically the incidence 
rate of  MSUI following radical prostatectomy was as high as 
87% [6]. However, contemporary series have reported lower 
incontinence rates ranging 4-50% after radical prostatectomy 
and approximately 1% following transurethral resection of  the 
prostate [7]. Pathophysiologic mechanisms of  postoperative 
MSUI include a direct injury to the urethral sphincter itself, as 
well as, to adj acent supportive tissues and nerves [8].
Although conservative and pharmacological management of  
low and intermediate grade MSUI may be effective particularly 
in a short-term, the maj ority of  patients will eventually require 
more invasive approach including sling procedure or artificial 
urinary sphincter (AUS) implantation [9]. Despite AUS 
recommendation as a current gold standard treatment option 
for men with postoperative stress urinary incontinence, with the 
resultant continence rates reaching 80%, it is associated with the 
substantial risk of  early and late complications, considerable cost 
and need for device revision at 5 years in up to 25% of  patients 
[10].
To date, only few studies have examined the efficacy of  
autologous adult-derived stem cells for the management of  
MSUI in human patients. Table I summarizes the clinical studies 
of  autologous mesenchymal-derived stem cells in men with SUI 
after prostatic surgery.
The first results for inj ection of  autologous myoblasts and 
fibroblasts obtained from skeletal muscle biopsies in 41 of  the 63 
male patients (65%) with SUI after radical prostatectomy were 
continent 12 months following inj ection of  autologous myoblasts 
and fibroblasts [11]. A significant improvement in quality of  life 
scores, the thicknesses of  the urethra and the rhabdosphincter, as 
well as, the increased contractility of  the rhabdosphincter were 
observed after a period of  1-year. Of  note, presence of  preoperative 
urethral strictures, scars, or fibrotic areas in the membranous part 
of  the urethra, as well as, prior treatment with bulking agents or 
internal urethrotomy, or pelvic irradiation negatively affected 
the success rates. The findings from both studies have supported 
validity of  MDSCs as a treatment option for male MSI. Further 
confirmatory data regarding the benefit of  MDSCs application 
for treatment of  MSUI have been reported by Cornu et al. [12]. 
In their study, authors observed improved urinary continence 
in all 12 patients who underwent intrasphincteric inj ections of  
autologous muscular cells isolated from a biopsy of  the deltoid 
muscle. Of  note, the efficacy results 1 year after the treatment 
were not homogeneous, with 4 out of  12 patients describing 
reduced urine leakage episodes, 1 out of  12 patients presenting 
increased maximal closure pressure, and 8 out of  12 patients 
showing improvement on pad-test.
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Table I. C lin ical s tud ies  o f au to logous m esenchym al-derived stem  cells  fo r m ale s tress urinary incontinence.
Author
[reference]
Number of male 







Mitterberger [11] 63 Severe MDSCs Biceps muscle 12 months No
Cornu [12] 12 ND MDSCs Deltoid muscle 12 months UTI in 3 men
Yamamoto [13] 3 Moderate ADSCs Anterior 
abdominal wall
6 months No
Gotoh [14] 11 ND ADSCs Anterior 
abdominal wall
12 months No
Key: MSUI=male stress urinary incontinence; ND=not described; MDSCs= muscle-derived stem cells; ADSCs= adipose-derived stem cells; UTI=urinary tract infection.
Table II. A uto logous s tem  cells  s tud ies  in fem ale  SUI.
Scientific centre Harvesting tissue Technique Biopsy muscle volume
Carr/ Chancellor 2008 [16] quadriceps femoris percutaneus needle technique Not given
Peters/ Chancellor 2014 [17] quadriceps femoris percutaneus needle technique 86±33 mg
Blaganje/Lukanovic 2012[18] upperarm open cut ~0.5 cm3
Stangel-Wójcikiewicz 2014 [19] deltoid muscle 14-G 10-cm
Ultra CORE Biopsy Needle (Angiotech, 
Gainesville, FL).
0.2g
Table III. C om parison o f techn iques, to o ls  o r sys tem s enab ling precise loca tion o f th e  urethra sph inc ter and th e  in jection spot.
Scientific centre Technique/tool Number of perisphincteral injections Cell's dose
Carr/ Chancellor 
2008 [16]
1. Transurethral injection with 8-mm Cook® Williams® 
cystoscopic injection needle
2. Transurethral injection with modiefied 10-mm 
Williams® needle
3. Periurethrally injection with 1,5-in. 25-gauge needle
2 injections
(at the 3 and 9 o'clock)
4 injections
(at the 3, 6, 9 and 12 o ’clock) 
4 injections





1. Cystoscopic guided tranurethral injection
2. Cystoscopic guided periurethral injection
3. Transurethral injection with the SUI Injection Needle 
(Cook Medical)






Sonoject, A.M.I, Feldkirch, Austriaw ith transurethral 8F 
ultrasound probe
26 depots of 50-100 gl each 
in to levels




Bulkamid® System; cystoscopic guided tranurethral 
injection
3 injections
(at 3, 12 and 9 o’clock)
0.6-25x106
MDC
Adipose-derived stem cells have also been investigated for 
treatment o f MSUI. Yamamoto et al. published their preliminary 
results regarding 3 male patients with moderate MSUI secondary 
to radical prostatectomy or holmium laser enucleation of the 
prostate (HoLEP) treated with ADSCs [13]. During a 6-month 
follow-up urinary incontinence progressively improved in all 
cases. This was evidenced by both functional and imaging 
studies. No significant adverse events were observed peri- and 
postoperatively.
Further support for the use o f ADSCs in the management of 
postoperative MSUI in men comes from the report by Gotoh et 
al. [14]. The results o f this recently published study on efficacy
of  autologous adipose-derived regenerative cells isolated from 
abdominal adipose tissue obtained by liposuction are encouraging. 
The authors observed a progressive improvement of  MSUI in 8 
out of  11 men during the 1-year follow-up which was shown by 
a 59% decrease in the leakage volume in the 24-hour pad test, an 
increase of  the maximum urethral closing pressure and functional 
profile length. There were no significant peri- or postoperative 
morbidity noted during the study period.
So far, all published studies evaluating periurethral inj ection 
of  autologous MDSCs and ADSCs in the management of  MSUI 
showed promising results. Moreover, this treatment modality 
seems to be a safe and feasible method for restoring urinary
N r 3 / 2 0 1 6  ©  P o l s k i e  T o w a r z y s t w o  G i n e k o l o g i c z n e  207
P R A C E  P O G L Ą D O W E
g in e k o lo g ia
DOI: 10.17772/gp/60973 G in e k o l  Po l.  2 0 1 6 ,  87 ,  2 0 5 - 2 1 0
Klaudia S tangel-W ojcikiew icz et al. Regenerative medicine- techniques and methods of administering autologous derived stem cells in urinary incontinence.
continence in male patients. However, since all currently available 
data come from small, single centre, noncomparable studies, as 
well as, have limited follow-up, further research is required to 
address all the aforementioned issues and subsequently provide 
an answer to the question about the role of  autologous adult 
mesenchymal-derived stem cells in the treatment of  SUI in men.
Tissue harvesting for female SUI treatment
Since 2001 numerous authors declare use of  different type 
of  autologous mesenchymal-derived stem cells in female SUI. 
The leakage improvement reached 80%, despite the number 
of  inj ected cells as well as the inj ection technique [15]. In the 
available literature, the following places and procedures of  
acquiring the tissue material are mentioned (Table II).
In research carried out by Chancellors group, the tissue biopsy 
was extracted from quadriceps femoris, a muscle which -  according 
to the scientists -  guarantees a sufficient amount oftissue for further 
cultivation [16, 17]. Lukanovic group reports open cut biopsie 
from location specified upper arm [18]. In order to minimize 
potential side effects as well as discomfort of  the patient, Stangel- 
Wój cikiewicz et al. carry out research using techniques known 
from biopsy of  lesions in the mammary gland [19]. An additional 
ultrasound scan allowed to eliminate vessels and bone tissue 
injury. In each of  the quoted research, the material was collected 
in on an outpatient basis, i.e. the patient could return to they 
daily activities right after the biopsy. No serious complications 
or permanent tissue damage at the extraction site were reported.
Cell’s injection techniques
Similarly to the methods of  tissue biopsy, also the techniques 
of  administering the cellular suspension are described in a 
different manner. This variety is especially noticeable in female 
SUI stem cells inj ections (Table III).
Depending on the facility, from 2 to 26 inj ections around the 
urethral sphincter were made, each time using endoscopic imaging 
(cystoscopy) or ultrasound imaging. In the research published 
in 2008 and 2011, Chancellor’s group applied the system of  
cytoscopy and administration through or perisphincteral, initially 
2 inj ections (at the 3 and 9 o ’clock), to increase the number of  
inj ections to 8 in the next study [16,17]. The volume of  the 
inj ected material was less then 4 ml, in order to avoid the so- 
called bulking agent effect. Higher dose groups tended to have 
greater percentages of  patients with at least a 50% reduction in 
stress leaks and pad weight at 12-month follow up. There was no 
technic indication to be more advantage to another. Lukanovic 
et al. used much more inj ections, namely 26 [18]. One may 
ponder on the fact of  stimulating local inflammatory reaction and 
secretion of  tissue growth factors as a response to such a large 
number of  inj ections. Does it have a stimulating or healing effect,
i.e. regeneration by administering cellular material?
In order to avoid this sort of  speculations, Stangel- 
Wój cikiewicz et al. decided to use one system of  inj ection 
(Bulkamid® System) and only three points, at the 3, 12 and 9 
o ’clock around the urethra sphincter (Figure 1) [19].
Its endoscopic imaging allows to keep the procedure 
comfortable, consisting, e.g., in control of  the potential bleeding 
from the inj ection points, control of  the amount of  administered 
suspension. Due to the anatomy of  the female urethra, they used 
a short, 11 cm optics with 0 degree angle.
Figure 1. Bulkamid® System.
Figure 2 (a, b). Injection system  (C ook Medical)
The available literature suggests that there is no single perfect, 
standard method of  administration. This diversity results from 
anatomic difficulties and phenotypic variability in the scope of  
urethra. Urethral sphincter has two primary components: internal 
sphincter, formed from smooth muscle layer, situated in the wall 
of  the near section of  urethra, which is probably an extension 
of  the detrusor muscle, and external sphincter, which surrounds 
the distal section of  the urethra and the vagina. On an outpatient 
basis, Stangel-Wój cikiewicz et al. accessed to few diagnostic 
methods which imperfectly represent both the aforesaid urethra 
sphincter and assess its functioning based on pressure changes. 
Ultrasonography (USG) and urodynamics (urethral pressure
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profile) only allow to determine the area which is anatomically 
referred to as the urethral sphincter.
The CookMedical system (Figure 2) uses the known length 
of  the urethra of  the given patient (measurement made earlier) 
and the assumption that the sphincter is located at one-third of  
its length. The inj ection is made after manual activation of  three 
needles at the height of  the mace-tipped guide. The syringe with 
the cellular material is connected to the system handle. One 
advantage of  this system may be the fact, that is a disposable 
system, and of  simple structure. Yet, its structure prevents any 
manoeuvring in the area of  the urethral sphincter and change of  
the inj ection angle, it also seems unusable in the case of  male 
patients.
In 2012, the engineers from the AGH Department of  
Robotics and Mechatronics in Krakow have initiated cooperation 
in order to jointly develop the technique for administration 
of  cell suspension. The obj ective of  the proj ect entitled 
“Micromanipulation with surgical instruments for assisting 
in intracorporeal procedures with the use of  vision imaging” -  
MACHWIZ (NCBiR), is the development of  practical methods 
of  designing devices for precise manipulation of  surgical 
instruments with visual feedback for handling the tools and 
additional imaging methods for location of  tissues or organs to 
be subj ected to the treatment. The work is focus on procedures 
within pelvis minor, performed with endoscopic tools through 
natural body orifices. Inj ecting stem cells in the urethral sphincter 
in treating stress urinary incontinence in female patients will be 
an example of  this type of  procedure, used for verification of  the 
developed method. The proper course of  use of  the designed tool 
will be verified in experimental tests conducted in a demonstration 
set fitted with a urologic phantom.
Figure 3. The developed endoscopic  robot tool -  s ide view.
Figure 4. The developed robot endoscopic  tool fo r MDC suspension injection 
-  isom etric view.
Robot aided MDC injection
Essential for the efficacy of  MDC treatment is the proper 
cells administration. This raises two problems: determination 
of  the correct place of  cell administration, and inj ection of  cell 
suspension precisely into the urethral sphincter. Solution of  the 
first problem is to choose an appropriate imaging method that 
allows for localisation, and preferably also for determine the 
spatial shape of  the urethral sphincter. Precise inj ection of  cell 
suspension exactly into the selected spot might be possible with 
the use of  the endoscopic assisting robot [20, 21].
To provide data in a digital format the use of  static USG 
images will be acquired before the procedure of  MDC inj ection. 
On-line, endoscopic vision system provide base imaging source. 
The automatic image processing collect data for tool navigation 
along the urethra. Actuators of  the needle extension and tool 
rotation allow for performing inj ection at the required depth and 
in the required place on the circumference of  the urethra. Urethral 
profilometry will be performed by the robot,j ust before inj ection, 
in a single tool insertion.
The designed instrument integrates endoscope optics, a 
custom detachable sheath and a drive mechanism for needle 
penetrating movement (Figure 3).
The chosen endoscope optics is the 7229 BA HOPKINS II 
forward-oblique version telescope , featuring a roller lens optic 
system, with incorporated fibre optics light transmission, offered 
by Karl Storz GmbH and Co. KG [22].
The detachable sheath has three internal leak-proof  channels. 
One of  them acts as a guide for an elastic hollow 23 Gauge 
needle, purposed for MDC inj ection. The two remaining conduits 
are responsible for wide-angle fluids dispersion (e.g. to inflate a 
collapsed urinary bladder), draining purposes or both.
The movement of  the needle is achieved by a precise and 
sophisticated mechanism. It is driven by a servomotor, consisting 
of  a low voltage DC motor, a suitable planetary gearbox and a 
rotary encoder[23]. The needle is guided in the sheath’s internal 
channel and bends in such a way that it leaves the tool at a steep 
angle to the urethral wall, piercing the mucous membrane and 
penetrating the urethral mucosa.
The endoscopic instrument can serve as a manual tool 
for surgeons if  attached to a telecam endoscope (20212030 
endoscope, Storz). If  integrated with the custom designed drive 
unit, it becomes an efficient end-effector for the pelvic surgery 
assisting robot (Figure 4).
The drive unit has two main obj ectives: to ensure a secure 
and reliable clutch between the instrument and the robot, and to 
provide rotation for the entire endoscopic tool, mimicking the 
swivel movement of  a human wrist. The unit is equipped with 
an adequate digital camera and an optic system, replacing the 
normally used telecams with no loss of  usage flexibility. It is 
also fitted with a universal socket for telescope mounting. The 
telescope can be quickly and easily detached at any time, without 
any additional tools [24].
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All the assembly elements of  the designed sheath are 
made of  the martensitic, precipitation-strengthened, corrosion- 
resistant X46Cr13 stainless steel [25], same as modern surgical 
instruments. The material and shape make the sheath fully 
autoclavable. The endoscopic instrument and drive units have 
low voltage electromechanical components located relatively far 
from both: the patient and the surgeon, ensuring safety against 
any electrical shocks. To ensure even further contamination 
safety, all the elements (beside the sheath) can be fitted within an 
elastic protective sleeve.
Conclusion
Scientific centres which researched the methods of  using 
cellular material for SUI treatment report (even within the scope 
of  a single research) various methods of  obtaining muscle tissue, 
as well as different ways of  inj ecting the cellular suspension 
into the urethra sphincter, with variable number of  insertions 
and quantity of  administered cells. The proper and repeatability 
administration technique might determinate the final results of  
stem cells base SUI treatment.
Oświadczenie autorów:
1. Klaudia Stangel-Wójcikiewicz -  autor koncepcji i założeń pracy, 
przygotowanie manuskryptu i piśmiennictwa -  autor zgłaszający i 
odpowiedzialny za manuskrypt.
2. Maciej Petko -  zebranie materiału, przygotowanie manuskryptu.
3. Konrad Kobus -  współautor tekstu pracy i protokołu, korekta i 
aktualizacja literatury.
4. Marcin Majka -  autor założeń pracy, analizy i interpretacji wyników, 
przygotowanie, korekta i akceptacja ostatecznego kształtu manuskryptu.
5. Tomasz Gołąbek -  współautor tekstu pracy, aktualizacja literatury.
6. Piotr Chłosta -  ostateczna weryfikacja i akceptacja manuskryptu.
7. Antoni Basta -  autor założeń pracy, ostateczna weryfikacja i akceptacja 
manuskryptu.
Źródło finansowania:
projekt finansowy z grantu PBS K/NCB/000003.
Konflikt interesów:
Autorzy nie zgłaszają konfliktu interesów oraz nie otrzymali żadnego 
wynagrodzenia związanego z powstawaniem pracy.
8. Radomski SB. Practical evaluation of post-prostatectomy incontinence. Can Urol Assoc J. 
2013, 7 (9-10 Suppl 4), S186-188.
9. Adamakis I, Vasileiou I, Constantinides CA. The treatment of iatrogenic male incontinence: latest 
results and future perspectives. Rev Recent Clin Trials. 2013, 8 (1), 36-41.
10. Herschorn S. The artif icial urinary sphincter is the treatment of choice for post-radical 
prostatectomy incontinence. Can Urol Assoc J. 2008, 2 (5), 536-539.
11. Mitterberger M, Marksteiner R, Margreiter E, [et al.]. Myoblast and f ibroblast therapy for post­
prostatectomy urinary incontinence: 1-year followup of 63 patients. J  Urol. 2008, 179 (1), 226­
231.
12. Cornu JN, Doucet C, Sebe P, [et al.]. Prospective evaluation of intrasphincteric injections 
of autologous muscular cells in patients with stress urinary incontinence following radical 
prostatectomy. Prog Urol. 2011, 21 (12), 859-865.
13. Yamamoto T, Gotoh M, Kato M, [et al.]. Periurethral injection of autologous adipose-derived 
regenerative cells for the treatment of male stress urinary incontinence: Report of three initial 
cases. Int J  Urol. 2012, 19 (7), 652-659.
14. Gotoh M, Yamamoto T, Kato M, [et al.]. Regenerative treatment of male stress urinary 
incontinence by periurethral injection of autologous adipose-derived regenerative cells: 1-year 
outcomes in 11 patients. Int J  Urol. 2014, 21 (3), 294-300.
15. Stangel-Wojcikiewicz K. Medycyna regeneracyjna w  leczeniu nietrzymania moczu. 
Wydawnictwo Uniwersytetu Jagiellońskiego, Kraków, 2014.
16. Carr LK, Steele D, Steele S, [et al.]. 1-year follow-up of autologous muscle-derived stem cell 
injection pilot study to treat stress urinary incontinence. Int Urogynecol J  Pelvic Floor Dysfunc. 
2008, 19, 881-883.
17. Peters K, Dmochowski R, Carr LK, [et al.]. Autologous muscle derived cells for treatment of 
stress urinary incontinence in women. J  Urol. 2014, 192 (2), 469-476.
18. Blaganje M, Lukanović A. Intrasphincteric autologous myoblast injections with electrical 
stimulation for stress urinary incontinence. Int J  Gynaecol Obstet. 2012, 117 (2), 164-167.
19. Stangel-Wojcikiewicz K, Jarocha D, Piwowar M, [et al.]. Autologous Muscle-Derived Cells for the 
Treatment of Female Stress Urinary Incontinence: A 2-Year Follow-Up of a Polish Investigation. 
Neurourol Urodyn. 2014, 33 (3), 324-330.
20. Hibner M, Marianowski P, Szymusik I, [et al.] [Robotic surgery in gynecology]. Ginekol Pol. 2012, 
83 (12), 934-938. Polish.
21. Stangel-Wójcikiewicz K, Basta A, Piwowar M, [et al.]. Operative procedures supported with 
robotics systems and available endoscope procedures in operative gynecology. Bio-Algorithms 
Med-Syst. 2014, 10 (3), 139-149.
22. Digital Imaging and Communications in Medicine (DICOM). National Electrical Manufacturers 
Association.; 2006. http://medical.nema.org/.
23. Petko M. Wybrane metody projektowania mechatronicznego. Radom: Wydawnictwo Naukowe 
Instytutu Technologii Eksploatacji -  PIB, Radom, 2008.
24. Yu T, Luo J, Singhal A, [et al.]. Shape regularized active contour based on dynamic programming 
for anatomical structure segmentation. In: Proc SPIE 5747, Medical Imaging 2005: Image 
Processing, . 2005.
25. Rosemann P, Kauss N, Muller C, [et al.]. Influence of solution annealing temperature and cooling 
medium on microstructure, hardness and corrosion resistance of martensitic stainless steel 
X46Cr13 Article f i rst published online: 29 JAN 2015
References
1. Abrams P, Andersson KE, Birder L, [et al.]. Fourth International Consultation on Incontinence 
Recommendations of the International Scientific Committee: Evaluation and treatment of urinary 
incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010, 29 (1), 
213-240.
2. Garely AD, Noor N. Diagnosis and surgical treatment of stress urinary incontinence. Obstet 
Gynecol. 2014, 124 (5), 1011-1027.
3. Yonguc T, Aydogdu O, Bozkurt IH, [et al.] .Long-term outcomes of transobturator tape procedure 
in women with stress and mixed urinary incontinence: 5-year follow-up. Minerva Urol Nefrol. 
2015, Jan 13. [Epub ahead of print]
4. Hart ML, Izeta A, Herrera-Imbroda B. , [et al.]. Cell therapy for stress urinary incontinence. Tissue 
Eng Part B  Rev 2015; , 21: , 365-376.
5. Hakim L, De Ridder D, Van der Aa F. Slings for urinary incontinence and the application of cell- 
based therapy. A dvD rug  DelivRev 2015; , 82-83: , 22-30.
6. Bauer RM, Bastian PJ, Gozzi C, Stief CG. Postprostatectomy incontinence: all about diagnosis 
and management. Eur Urol. 2009, 55 (2), 322-333.
7. Herschorn S, Bruschini H, Comiter C, Grise P, Hanus T, Kirschner-Hermanns R, Abrams P;[et 
al.]. Committee of the International Consultation on Incontinence.Surgical treatment of stress 
incontinence in men. Neurourol Urodyn. 2010, 29 (1), 179-190.
2 1 0  ©  P o l s k i e  T o w a r z y s t w o  G i n e k o l o g i c z n e  Nr 3 / 2 0 1 6
